Cat. No.: HY-135115

Oleuropein Aglycone

Name: Oleuropein Aglycone
Brand: MedChemExpress
SKU: HY-135115
Price: 190.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: 3,4-DHPEA-EA)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Oleuropein Aglycone (3,4-DHPEA-EA) is a secoiridoid that exerts antioxidant, anti-inflammatory, and anti-apoptotic effects by promoting ERK/AMPK/eNOS phosphorylation and inhibiting JNK/p38 MAPK and inflammation-related signaling pathways. Oleuropein Aglycone is used in research on acute kidney injury induced by ischemia-reperfusion injury, pleurisy, osteoporosis, Alzheimer's disease, neurodegenerative diseases, and triple-negative breast cancer.

For research use only. We do not sell to patients.

Purity : 98.46%
CAS No.: 31773-95-2
Formula: C₁₉H₂₂O₈
Molecular Weight:378.37

Storage:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Oleuropein Aglycone Chemical Structure

CAS No.: 31773-95-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All ERK Isoforms :

All AMPK Isoforms :

All NO Synthase Isoforms :

All JNK Isoforms :

All p38 MAPK Isoforms :

In Vitro

Aβ/Tau/α-Synuclein AggregationAnti-cancerOxidative StressCytokines & ChemokinesInnate ImmunityOthers

Aβ/Tau/α-Synuclein Aggregation

Oleuropein Aglycone (3,4-DHPEA-EA) (1:0-1:10; 50 h) significantly inhibits S100A9 amyloid formation by reducing the effective rate of amyloid growth and the overall amyloid burden^[4].
Oleuropein aglycone (1:0-1:10; 6-48 h) reduces the length and number of S100A9 amyloid fibrils and protein oligomerization in a concentration-dependent manner^[4].
Oleuropein aglycone (137 μM) depolymerizes preformed S100A9 fibrils and converts them into non-fibrillar aggregates^[4].
Oleuropein aglycone inhibits the development of S100A9 amyloid and reduces the β-sheet content in preformed fibrils^[4].
Oleuropein aglycone interacts with both native and amyloid S100A9, with apparent dissociation constants of 0.5 and 200 μM^[4].
Oleuropein aglycone (1:2; 1-48 h) depolymerizes preformed S100A9 fibrils into non-fibrillar aggregates that are no longer toxic^[4].
Oleuropein aglycone (1:1-1:10; 10-60 min) attenuates the S100A9 amyloid-induced increase in intracellular free Ca²⁺ levels in SH-SY5Y cells, returning to baseline levels at S100A9 to OleA molar ratios of 1:5 and 1:10^[4].
Oleuropein aglycone (1:1-1:10; 24 h) targets S100A9 amyloid on the cell membrane and reduces its accumulation in GM1-containing membrane rafts^[4].

Anti-cancer

Aβ/Tau/α-Synuclein Aggregation

Oleuropein aglycone (1:1-1:10; 24 h) attenuates S100A9-induced cytotoxicity in SH-SY5Y cells, achieving complete recovery at S100A9 to Oleuropein aglycone molar ratios of 1:5 and 1:10^[4].

Oxidative Stress

Anti-cancer

Oleuropein aglycone (1:1-1:10; 24 h) reduces ROS production in S100A9-induced SH-SY5Y cells, returning to baseline levels at S100A9 to OleA molar ratios of 1:5 and 1:10^[4].

Oxidative Stress

Oleuropein aglycone (0.78-100 mM; 40 min) exhibits antioxidant activity in the DPPH assay with an IC₅₀ of 25.23 μM^[5].
Oleuropein Aglycone (compound 4) (10 μM) exhibits peroxyl radical scavenging capacity, with an ORAC_FL value of 60.1 μM^[10].
Oleuropein Aglycone (100 μM; 24 h) significantly reduces H₂O₂-induced intracellular ROS generation in HeLa cells^[10].

Anti-cancer

Oleuropein Aglycone (1-100 µM; 24 h) exhibits low cytotoxicity in young HUVECs, RS-HUVECs, THP-1, and hSAECs, with cell viability remaining at least 85% at concentrations up to 5 µM^[7].
Oleuropein Aglycone (IC₅₀; 24 h) significantly increases γH2A.X levels in MDA-MB-231 cells to approximately 165% of the control, exhibiting the greatest effect among the tested olive oil phenolics^[9].

Cytokines & Chemokines

Innate Immunity

Oleuropein Aglycone (5 µM; 2 h) reduces IL-1β and IL-8 mRNA expression and IL-6 secretion in LPS-stimulated young HUVECs^[7].

Innate Immunity

Anti-cancer

Oleuropein Aglycone (5 µM; 2 h) downregulates TNF-α and IL-8 mRNA expression and reduces IL-6 production in LPS-stimulated THP-1 cells^[7].

Cytokines & Chemokines

Innate Immunity

Oxidative Stress

Oleuropein Aglycone (5 µM; 24 h) exerts anti-SASP activity by reducing the expression of IL-1β, TNF-α, ICAM-1, and VCAM, and decreasing IL-6 release in RS-HUVECs^[7].

Innate Immunity

Oleuropein Aglycone (5 µM; 2 h) decreases IL-1β and SOD2 mRNA expression, reduces IL-6 release, lowers ACE2 mRNA, and downregulates P-NF-kB and ACE2 protein levels in Polyinosinic-polycytidylic acid (Poly (I:C)) (HY-107202)-stimulated hSAECs^[7].

Others

Oleuropein Aglycone (5-100 μM; 24 h) is well tolerated by human BMSCs, and a concentration of 5 μM maintains at least 85% cell viability^[3].
Oleuropein Aglycone (180 °C; 3 h) is mostly degraded in heated extra virgin olive oil, with only 6% remaining^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

Human bone marrow mesenchymal stromal cells (BMSCs)
Concentration:

5, 10, 25, 50, 100 μM; 5 μM (selected for further experiments)
Incubation Time:

24 h
Result:

Determined the concentration of oleuropein aglycone that would ensure at least 85% cell viability to be 5 μM.

Cell Differentiation Assay^[3]

Cell Line:

Human bone marrow mesenchymal stromal cells (BMSCs)
Concentration:

5 μM
Incubation Time:

14 days
Result:

Induced a more modest reduction in intracellular lipid droplet accumulation.
Showed a reduction in the percentage of stained area in OA-treated ADMSCs compared to untreated ADMSCs.

Cell Cytotoxicity Assay^[4]

Cell Line:

SH-SY5Y cells
Concentration:

S100A9 to OleA molar ratio of 1:2
Incubation Time:

1 to 48 h
Result:

A decrease of the cytotoxic effect of the preformed S100A9 amyloids was observed when they were treated with OleA.

Cell Proliferation Assay^[5]

Cell Line:

SH-SY5Y
Concentration:

0.5, 1, 10, 100 μM
Incubation Time:

24 h
Result:

At a concentration of 0.1 μM, the percentage of control cell growth was almost 100%.

Cell Viability Assay^[7]

Cell Line:

Young HUVECs, Replicative Senescent HUVECs (RS-HUVECs), THP-1 monocytic cells, and primary human small airway epithelial cells (hSAECs)
Concentration:

5, 10, 25, 50, 100 μM (0.36-36 µg/mL)
Incubation Time:

24 h
Result:

Maintained at least 85% cell viability at concentrations up to 5 µM.

Real Time qPCR^[7]

Cell Line:

Young HUVECs
Concentration:

5 µM
Incubation Time:

2 h (pre-treatment); 3 h (LPS stimulation)
Result:

Inhibited IL-1β and IL-8 mRNA expression.
Exerted a significant reduction in IL-6 secretion.

Real Time qPCR^[7]

Cell Line:

THP-1 monocytic cells
Concentration:

5 µM
Incubation Time:

2 h (pre-treatment); 3 h (LPS stimulation)
Result:

Significantly reduced TNF-α and IL-8 mRNA expression.
Significantly reduced the production of IL-6 evaluated in cell lysates.

Real Time qPCR^[7]

Cell Line:

Replicative senescent HUVECs (RS-HUVECs)
Concentration:

5 µM
Incubation Time:

24 h
Result:

Significantly reduced the mRNA expression of IL-1β, TNF-α, ICAM-1, and VCAM.
Efficiently reduced IL-6 release in the conditioned medium.
Observed a slight, but not significant, increase in SOD2 expression.

Real Time qPCR^[7]

Cell Line:

Human small airway epithelial cells (hSAECs)
Concentration:

5 µM
Incubation Time:

2 h (pre-treatment); 24 h (Poly(I:C) treatment)
Result:

Significantly lowered IL-1β and SOD2 mRNA expression.
Significantly reduced IL-6 release.
Significantly downregulated P-NF-kB protein expression.
Significantly reduced ACE2 mRNA and downregulated ACE2 protein level.
Did not affect TMPRSS2 protein expression.

In Vivo

Innate ImmunityOxidative StressAnti-cancer

Innate Immunity

Oxidative Stress

Oleuropein Aglycone (3,4-DHPEA-EA) (40-100 μM/kg; i.p.) attenuates carrageenan-induced acute inflammation in mice by reducing lung injury, neutrophil infiltration, adhesion molecule expression, pro-inflammatory cytokine release, NO production, nitrotyrosine formation, lipid peroxidation, and PARP activation^[2].

Anti-cancer

Oleuropein aglycone induces tumor regression in mice within 9-12 days^[6].
Oleuropein aglycone (12.5 mg/kg; i.p.; three times per week; until day 35) reduces endpoint tumor burden by 22.0% in a TNBC xenograft mouse model ^[9].
Oleuropein aglycone (6.25 mg/kg; i.p.; three times per week; until day 35) and 2.5 mg/kg OLC retain antitumor activity, reducing endpoint tumor burden by 23.7% in a TNBC xenograft mouse model^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CD mice (male, 20-25 g)^[2]
Dosage:

100 μM/kg; 40 μM/kg
Administration:

i.p.; 30 min after carrageenan challenge
Result:

Reduced the degree of lung injury.
Attenuated neutrophil infiltration into the lung tissue.
No positive staining for ICAM-1 or P-selectin was observed in the lungs.
Attenuated the release of TNF-α and IL-1β in pleural exudates.
Significantly reduced NO exudate levels.
No positive staining for nitrotyrosine was found in the lungs.
Significantly attenuated lipid peroxidation in the lungs.
Reduced the degree of PARP activation.

Animal Model:

CB17-SCID (cr-Prkdcscid/scid/Rj) mice^[9]
Dosage:

12.5 mg/kg
Administration:

i.p.; three times per week; until Day 35
Result:

Reduced endpoint tumor weight to 0.23 g, corresponding to a 22.0% decrease compared with the vehicle control group.

Animal Model:

CB17-SCID (cr-Prkdcscid/scid/Rj) mice^[9]
Dosage:

6.25 mg/kg
Administration:

i.p.; three times per week; until Day 35
Result:

Decreased endpoint tumor weight to 0.225 g, corresponding to a 23.7% reduction compared with the vehicle control group.

Related Protocols :

Chemical Information

CAS No. 31773-95-2
Appearance Oil
Molecular Weight 378.37
Formula C₁₉H₂₂O₈
Color Off-white to light yellow
SMILES

O=C(OCCC1=CC=C(O)C(O)=C1)C[C@H]2/C([C@H](O)OC=C2C(OC)=O)=C\C
Synonyms

3,4-DHPEA-EA
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (1)

All

Sort by:

Journal Impact Factor

Nutraceuticals

2026 Jun;6(2):24.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (132.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6429 mL

13.2146 mL

26.4292 mL

5 mM

0.5286 mL

2.6429 mL

5.2858 mL

10 mM

0.2643 mL

1.3215 mL

2.6429 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (297 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nasrallah H, et al. Effect of oleuropein on oxidative stress, inflammation and apoptosis induced by ischemia-reperfusion injury in rat kidney. Life sciences. 2020 Aug 15;255:117833.

[2]. Impellizzeri D, et al. The effects of oleuropein aglycone, an olive oil compound, in a mouse model of carrageenan-induced pleurisy. Clinical nutrition (Edinburgh, Scotland). 2011 Aug;30(4):533-40.

[3]. Giordani C, et al. Differential Impact of Olive Leaf Extract and Its Secoiridoid Components, Oleuropein Aglycone and Oleacin, on Adipogenic Differentiation and Proliferation of Bone Marrow Mesenchymal Stem Cells. Pharmaceuticals (Basel, Switzerland). 2026 Feb 25;19(3):353.

[4]. Leri M, et al. Natural Compound from Olive Oil Inhibits S100A9 Amyloid Formation and Cytotoxicity: Implications for Preventing Alzheimer's Disease. ACS chemical neuroscience. 2021 Jun 02;12(11):1905-1918.

[5]. Nardi M, et al. Hydroxytyrosol oleate: A promising neuroprotective nanocarrier delivery system of oleuropein and derivatives. International Journal of Pharmaceutics. 2023 Jan 25;631:122498.

[6]. Charoenprasert S, et al. Factors influencing phenolic compounds in table olives (Olea europaea). Journal of agricultural and food chemistry. 2012 Jul 25;60(29):7081-95.

[7]. Silvestrini A, et al. Anti-Inflammatory Effects of Olive Leaf Extract and Its Bioactive Compounds Oleacin and Oleuropein-Aglycone on Senescent Endothelial and Small Airway Epithelial Cells. Antioxidants (Basel, Switzerland). 2023 Jul 28;12(8):1509.

[8]. Castiglioni B, et al. Antioxidant and Anti-Osteoclastogenic Potential of Olive Oil Dregs Extracts. Molecules. 2026 Sep 10;31(18):3178.

[9]. Madelou NA, et al. Time-Dependent Multimechanistic Antitumor Effects of Olive Oil Phenolics in a Triple-Negative Breast Cancer Mouse Model. Nutrients. 2026 Aug 23;18(17):2756. [Content Brief]

[10]. Nardi M, et al. Biomimetic synthesis and antioxidant evaluation of 3,4-DHPEA-EDA [2-(3,4-hydroxyphenyl) ethyl (3S,4E)-4-formyl-3-(2-oxoethyl)hex-4-enoate]. Food chemistry. 2014 Nov 01;162:89-93.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6429 mL	13.2146 mL	26.4292 mL	66.0729 mL
	5 mM	0.5286 mL	2.6429 mL	5.2858 mL	13.2146 mL
	10 mM	0.2643 mL	1.3215 mL	2.6429 mL	6.6073 mL
	15 mM	0.1762 mL	0.8810 mL	1.7619 mL	4.4049 mL
	20 mM	0.1321 mL	0.6607 mL	1.3215 mL	3.3036 mL
	25 mM	0.1057 mL	0.5286 mL	1.0572 mL	2.6429 mL
	30 mM	0.0881 mL	0.4405 mL	0.8810 mL	2.2024 mL
	40 mM	0.0661 mL	0.3304 mL	0.6607 mL	1.6518 mL
	50 mM	0.0529 mL	0.2643 mL	0.5286 mL	1.3215 mL
	60 mM	0.0440 mL	0.2202 mL	0.4405 mL	1.1012 mL
	80 mM	0.0330 mL	0.1652 mL	0.3304 mL	0.8259 mL
	100 mM	0.0264 mL	0.1321 mL	0.2643 mL	0.6607 mL

Bioz

Oleuropein Aglycone

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Oleuropein Aglycone

Publications Citing Use of MedChemExpress (MCE) Oleuropein Aglycone

All ERK Isoforms

All AMPK Isoforms

All NO Synthase Isoforms

All JNK Isoforms

All p38 MAPK Isoforms